Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain

BACKGROUND AND OBJECTIVES: To examine the efficacy of ubrogepant in the treatment of migraine with mild vs moderate or severe pain. METHODS: This was a phase 3, open-label, dose-blinded, 52-week extension trial. Adults with migraine were randomized 1:1:1 (usual care, ubrogepant 50 mg, or ubrogepant...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Dodick, David W., Goadsby, Peter J., Burstein, Rami, Adams, Aubrey M., Lai, Jeff, Yu, Sung Yun, Finnegan, Michelle, Kuang, Amy W., Trugman, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620813/
https://www.ncbi.nlm.nih.gov/pubmed/35977836
http://dx.doi.org/10.1212/WNL.0000000000201031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620813/
https://www.ncbi.nlm.nih.gov/pubmed/35977836
http://dx.doi.org/10.1212/WNL.0000000000201031

Ejemplares similares